Pembrolizumab‐induced interstitial lung disease following thoracic surgery in a patient with non‐small cell lung cancer

The safety of treatment with immune‐checkpoint inhibitors prior to thoracic surgery in patients with non‐small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62‐year‐old woman with NSCLC with programmed death ligand 1 expression on 85% of tumor cells. The patient was initi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Thorac Cancer
Päätekijät: Fujita, Tetsuo, Hayama, Nami, Kuroki, Tsuguko, Shiraishi, Yuka, Amano, Hiroyuki, Nakamura, Makoto, Hirano, Satoshi, Aramaki, Nao, Ichinose, Shuji, Shimizu, Shinichiro, Tabeta, Hiroshi, Nakamura, Sukeyuki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons Australia, Ltd 2019
Aiheet:
Case Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825914/
https://ncbi.nlm.nih.gov/pubmed/31512401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13194
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia